19 May 2017

Targeting the Ubiquitin - Proteasome Pathway

Organised by:

Birmingham

Registration Closed

This event is no longer available for registration.

Synopsis

Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.
The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.

Programme

Event Day - 19 May 2017

Day's schedule

10:00: Registration and refreshments
10:25: Opening remarks
10:30: PROTACs: Induced Protein Degradation as a Therapeutic Strategy Craig Crews, Yale Center for Molecular Discovery
11:30: Ubiquitin system modulation: strategies and technologies Satpal Virdee, University of Dundee
12:00: Chemical Ubiquitination Huib Ovaa, Leiden University Medical Centre
12:30: Lunch and exhibiton
14:00: From Pan-Kinase Promiscuity to Selective Degradation using PROTACs Christopher Tinworth, GlaxoSmithKline
14:30: Inhibitors of the E2 ubiquitin conjugating enzyme Rad6: discovery and anticancer properties Andrew Westwell, Cardiff University
15:00: Refreshments and exhibition
15:30: Enabling and supporting ubiquitin system targeted drug discovery Jason Brown, Ubiquigent
16:00: Ubiquitin -Omics for Target Discovery in Human Disease Benedikt Kessler, Nuffield Department of Medicine
16:30: Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras Tom Heightman, Astex Pharmaceuticals
17:00: Closing remarks and conference close.

Venue and Contact

SCI

The Studio Birmingham
7 Cannon Street,
Birmingham
B2 5EP

Please click here for a location map.

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Fees

Early bird fees before Tuesday 18 April 2017

GB£80 . . . . . . . . . . . . . . . . . SCI Member
GB£35 . . . . . . . . . . . . . . . . . SCI Student Member
GB£50 . . . . . . . . . . . . . . . . . SCI Subsidised Member
GB£120 . . . . . . . . . . . . . . . . Non-Member

Standard fees after Tuesday 18 April 2017

GB£130 . . . . . . . . . . . . . . . . SCI Member
GB£50 . . . . . . . . . . . . . . . . . SCI Student Member
GB£70 . . . . . . . . . . . . . . . . . SCI Subsidised Member
GB£170 . . . . . . . . . . . . . . . . Non-Member

SCI Platinum Corporate Members receive 25% off the above rates

Become an SCI Member and save on this and future events

See Membership Options

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Exhibitors

Additional Info

Exhibition and Sponsorship

For further information and prices please email conferences@soci.org

Keynote speaker

Craig Crews, Yale Center for Molecular Discovery
PROTACs: Induced Protein Degradation as a Therapeutic Strategy